Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use

Aims

[1]  N. Harbeck,et al.  HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. , 1999, International journal of oncology.

[2]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[3]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[4]  C. Jackisch,et al.  Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. , 1998, The American journal of pathology.

[5]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[6]  G. Assmann,et al.  Isolation of blood‐borne epithelium‐derived c‐erbB‐2 oncoprotein‐positive clustered cells from the peripheral blood of breast cancer patients , 1998, International journal of cancer.

[7]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.

[8]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Wells,et al.  The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[10]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Barnekow,et al.  Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes. , 1997, DNA and cell biology.

[12]  D. Stern,et al.  Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. , 1996, British Journal of Cancer.

[13]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[14]  G. Assmann,et al.  Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. , 1995, Gene.

[15]  D. Stern,et al.  Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. , 1995, Cancer research.

[16]  N. Altorki,et al.  Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. Bankfalvi,et al.  Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry , 1994, The Journal of pathology.

[18]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[19]  D N Poller,et al.  Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. , 1993, Clinical radiology.

[20]  S. Cha,et al.  HER‐2/neu expression: A major prognostic factor in endometrial cancer , 1992, Gynecologic oncology.

[21]  H. Frierson,et al.  c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[22]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[24]  P. V. van Diest,et al.  Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material. , 1991, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[25]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[26]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[27]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[28]  M. J. van de Vijver,et al.  Amplification and over-expression of the neu oncogene in human breast carcinomas. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[30]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[31]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[32]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[33]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[34]  J. Ingle,et al.  Increased HER2 with U.S. Food and Drug Administration-approved antibody. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Hung,et al.  Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer , 1992, Molecular carcinogenesis.